SEC-sourced researchBeta
GYRE
GYRE THERAPEUTICS, INC.
Company comparison ↗
Data passport
- CIK
- 0001124105
- Exchange
- Nasdaq
- Business activity
- — · SIC 2834
- Financial inputs
- 6/6
- Filing date
- Sep 1, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2024 | 105,757,000.0000 | Mar 13, 2026 |
| December 2025 | 116,588,000.0000 | Mar 13, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 116,588,000.0000 | 9,880,000.0000 | 1,010,000.0000 | 166,132,000.0000 | 23,850,000.0000 | Mar 13, 2026 |
| December 2024 | 105,757,000.0000 | 17,898,000.0000 | -3,641,000.0000 | 125,406,000.0000 | 27,004,000.0000 | Mar 13, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $116.59M | December 2025 | Mar 13, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $105.76M | December 2024 | Mar 13, 2026 | 10-K |
| Net incomeNetIncomeLoss | $9.88M | December 2025 | Mar 13, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $1.01M | December 2025 | Mar 13, 2026 | 10-K |
| Total assetsAssets | $166.13M | December 2025 | Mar 13, 2026 | 10-K |
| Total liabilitiesLiabilities | $23.85M | December 2025 | Mar 13, 2026 | 10-K |